Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TNM, NPT

RTI International acquires Medical Data Analytics


RESEARCH TRIANGLE PARK, N.C., April 6, 2020 /PRNewswire/ -- RTI International has closed on its acquisition of Medical Data Analytics (MDA), a provider of real-world evidence (RWE) generation to the pharmaceutical and biotechnology industry. The acquisition expands existing services of the RTI Health Solutions business unit in design and conduct of observational research with MDA's capabilities in data collection and management, and physician and site recruitment.

"This acquisition fits directly with RTI's corporate strategy of investing in our pharmaceutical services and commercial research business lines," said E. Wayne Holden, PhD, president and CEO of RTI International. "We are pleased to welcome the Medical Data Analytics team to RTI as we offer our clients deeper insights into the patient journey through the generation of clinical and economic evidence."

MDA employs a scientific, rigorous, and efficient method of data collection that uses screened and verified physicians as study investigators for data collection and validation.

"We're pleased to have such a talented group of people joining our team. We look forward to ongoing collaboration with our new colleagues and are excited to have their expertise as we continue to strengthen our competitive position in the real-world evidence space," said Chris Simmons, senior vice president of RTI Health Solutions.

The expertise of the MDA team will enhance RTI Health Solutions' capabilities in providing non-interventional, retrospective, prospective, and ambispective medical chart reviews and patient-reported outcomes studies.

"RTI Health Solutions has a strong reputation for high-quality scientific delivery," said Nicole Siamas, MDA president and managing partner. "MDA's core capabilities in study design and collection of real-world outcomes data are a natural fit to expand RTI Health Solutions capacity for delivering a robust and integrated set of project services for our clients."

MDA will operate as a separate business operation of RTI Health Solutions for a period of time to facilitate an orderly transition that allows both organizations to continue to deliver excellent service to their clients. All employees of MDA are expected to remain with the business following this transaction.

Deal terms were not disclosed. 

RTI Health Solutions

As a business unit of RTI InternationalRTI Health Solutions provides global biopharmaceutical companies research and consulting services in health economics, patient-centered outcomes assessment, health preference assessment, surveys and observational studies, market access, epidemiology, biostatistics, and clinical research services. As the only non-profit, independent organization of its kind, its 330-person multidisciplinary team?most of them master's- and PhD-level researchers?brings a balanced approach of scientific rigor and industry context to projects.

About RTI International
RTI International is an independent, nonprofit research institute dedicated to improving the human condition. Clients rely on us to answer questions that demand an objective and multidisciplinary approach ? one that integrates expertise across the social and laboratory sciences, engineering and international development. We believe in the promise of science, and we are inspired every day to deliver on that promise for the good of people, communities and businesses around the world. For more information, visit www.rti.org.

SOURCE RTI International


These press releases may also interest you

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...



News published on and distributed by: